Overall Assessment
Limited Methodological Quality
Assessment created by PaperScorers Medical AI v0.1.0 on Jan 7, 2026
Key Takeaways
- •iPS cells discovered via four-factor reprogramming transformed research, less so clinic to date.
- •Clinical translation is slow; early trial paused over genetic variants; banking likely key.
- •iPS cells excel in disease modelling, organoids, and drug screening; CRISPR synergy.
- •Major challenges: quality control, line-to-line variability, ageing models for late-onset disease.
- •Improved non-integrating methods and gene editing enhance safety and precision.
Conclusion
A balanced decade review: iPS cells reshaped biology and preclinical research; clinical therapies remain cautious and methodically progressing.
Quick Actions
Quality Dimensions
Integrity & Transparency
Premise
Literature Positioning
Study Provenance
Methodological Assessment
Quick Actions
Study Overview
Publication Details
External Resources
Disclaimer: This assessment is generated by AI and should not be the sole basis for clinical or research decisions. Always review the original paper and consult with domain experts.
Suggested Papers
From Our Blog
Understanding Sample Size: How Many Patients is Enough?
Sample size determines the reliability of a study. Small studies are like low-resolution photos: you cannot trust the details.
Funnel Plots: The Shape of Bias
How do you see invisible studies? A funnel plot reveals the papers that were never published.
The Placebo Effect: It Is Not Just 'In Your Head'
The placebo effect is a real biological response. If a new drug cannot beat a sugar pill, it is useless. Here is why your brain is the most powerful pharmacy.